These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 17408366)

  • 21. Transmissible spongiform encephalopathies.
    Sejvar JJ; Schonberger LB; Belay ED
    J Am Vet Med Assoc; 2008 Dec; 233(11):1705-12. PubMed ID: 19046027
    [No Abstract]   [Full Text] [Related]  

  • 22. Prion protein-specific antibodies-development, modes of action and therapeutics application.
    Rovis TL; Legname G
    Viruses; 2014 Oct; 6(10):3719-37. PubMed ID: 25275428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transmissible spongiform encephalopathies: prion proof in progress.
    Edskes HK; Wickner RB
    Nature; 2004 Aug; 430(7003):977-9. PubMed ID: 15329705
    [No Abstract]   [Full Text] [Related]  

  • 24. DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge.
    Fernandez-Borges N; Brun A; Whitton JL; Parra B; Diaz-San Segundo F; Salguero FJ; Torres JM; Rodriguez F
    J Virol; 2006 Oct; 80(20):9970-6. PubMed ID: 17005675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A short review of transmissible spongiform encephalopathies, and guidelines for managing risks associated with chronic wasting disease in captive cervids in zoos.
    Travis D; Miller M
    J Zoo Wildl Med; 2003 Jun; 34(2):125-33. PubMed ID: 12885128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunisation strategies against prion diseases: prime-boost immunisation with a PrP DNA vaccine containing foreign helper T-cell epitopes does not prevent mouse scrapie.
    Nitschke C; Flechsig E; van den Brandt J; Lindner N; Lührs T; Dittmer U; Klein MA
    Vet Microbiol; 2007 Aug; 123(4):367-76. PubMed ID: 17499458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unraveling the details of prion (con)formation(s): recent advances by mass spectrometry.
    Principe S; Maras B; Schininà ME; Pocchiari M; Cardone F
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):697-707. PubMed ID: 18729021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases.
    Zuber C; Knackmuss S; Rey C; Reusch U; Röttgen P; Fröhlich T; Arnold GJ; Pace C; Mitteregger G; Kretzschmar HA; Little M; Weiss S
    Mol Immunol; 2008 Jan; 45(1):144-51. PubMed ID: 17576014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of monoclonal antibody that distinguishes PrPSc from PrPC and neutralizes prion infectivity.
    Horiuchi M; Karino A; Furuoka H; Ishiguro N; Kimura K; Shinagawa M
    Virology; 2009 Nov; 394(2):200-7. PubMed ID: 19766283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transgenic mouse models of prion diseases.
    Telling GC
    Methods Mol Biol; 2008; 459():249-63. PubMed ID: 18576160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retinal function and morphology are altered in cattle infected with the prion disease transmissible mink encephalopathy.
    Smith JD; Greenlee JJ; Hamir AN; Richt JA; Greenlee MH
    Vet Pathol; 2009 Sep; 46(5):810-8. PubMed ID: 19429980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. More tools for prion research.
    Bradbury J
    Drug Discov Today; 2004 Oct; 9(19):821-2. PubMed ID: 15381128
    [No Abstract]   [Full Text] [Related]  

  • 33. Prions: transmissible spongiform encephalopathies and dental transmission risk assessment.
    Hamilton J
    J Calif Dent Assoc; 2007 Jan; 35(1):30-42. PubMed ID: 17269286
    [No Abstract]   [Full Text] [Related]  

  • 34. Prion disease: the implications for dentistry.
    Azarpazhooh A; Fillery ED
    J Endod; 2008 Oct; 34(10):1158-66. PubMed ID: 18793912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of genuine prion infectivity by serial PMCA.
    Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
    Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis of prion diseases: current status and future outlook.
    Aguzzi A; Heikenwalder M
    Nat Rev Microbiol; 2006 Oct; 4(10):765-75. PubMed ID: 16980938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development of molecular target based-therapy for prion diseases].
    Sakasegawa Y; Doh-ura K
    Brain Nerve; 2007 Apr; 59(4):405-14. PubMed ID: 17447527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
    Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
    Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Newly discovered forms of prion diseases in ruminants].
    Laude H; Béringue V
    Pathol Biol (Paris); 2009 Mar; 57(2):117-26. PubMed ID: 18848406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insights into prion strains and neurotoxicity.
    Aguzzi A; Heikenwalder M; Polymenidou M
    Nat Rev Mol Cell Biol; 2007 Jul; 8(7):552-61. PubMed ID: 17585315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.